SAFETY AND EFFICACY OF LUMACAFTOR/IVACAFTOR IN PEDIATRIC CYSTIC FIBROSIS PATIENTS

被引：0
|
作者：
Wainwright, C. [1 ]
Chilvers, M. [2 ]
Hug, C. [3 ]
Marigowda, G. [3 ]
Tian, S. [3 ]
Solomon, M. [4 ]
Black, P. [5 ]
Rosenfeld, M. [6 ]
Sawicki, G. [7 ]
Hoppe, J. [8 ]
机构：
[1] Lady Cilento Childrens Hosp, South Brisbane, Australia
[2] British Columbia Childrens Hosp, Vancouver, BC, Canada
[3] Vertex Pharmaceut Inc, Boston, MA USA
[4] Hosp Sick Children, Toronto, ON, Canada
[5] Childrens Mercy Hosp, Kansas City, MO 64108 USA
[6] Univ Washington, Sch Med, Seattle Childrens Hosp, Seattle, WA 98195 USA
[7] Harvard Med Sch, Boston, MA USA
[8] Univ Colorado, Sch Med, Childrens Hosp Colorado, Boulder, CO 80309 USA
来源：
RESPIROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TP 068
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [41] Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
    Cholon, Deborah M.
    Esther, Charles R., Jr.
    Gentzsch, Martina
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (03): : 235 - 243
  • [42] Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
    C. Colombo
    A. Foppiani
    A. Bisogno
    S. Gambazza
    V. Daccò
    E. Nazzari
    A. Leone
    A. Giana
    A. Mari
    A. Battezzati
    Journal of Endocrinological Investigation, 2021, 44 : 2213 - 2218
  • [43] The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis
    Hammond, James A.
    Connett, Gary J.
    PAEDIATRIC RESPIRATORY REVIEWS, 2018, 27 : 16 - 17
  • [44] Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
    Colombo, C.
    Foppiani, A.
    Bisogno, A.
    Gambazza, S.
    Dacco, V
    Nazzari, E.
    Leone, A.
    Giana, A.
    Mari, A.
    Battezzati, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (10) : 2213 - 2218
  • [45] Multi-Omics Profiling of Lumacaftor/Ivacaftor Response in Cystic Fibrosis
    Kopp, B. T.
    Fitch, J. R.
    Zhang, S.
    Shrestha, C. L.
    Woodley, F. W.
    Hayes, D.
    White, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [46] Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis Keeping It Real
    Sala, Marc A.
    Jain, Manu
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (02) : 133 - 134
  • [47] Safety and effectiveness of lumacaftor-ivacaftor in adults with cystic fibrosis: A single-center Canadian experience
    Sergeev, Valentine
    Desai, Sameer
    Flores, Eri
    Kerr, Jane
    Su, Victoria
    Wilcox, Pearce
    Quon, Bradley S.
    CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE, 2020, 4 (03) : 174 - 179
  • [48] Characterization Of Ivacaftor And Lumacaftor Using Biomap® Profiling - Implications For Cystic Fibrosis
    Velichko, S.
    Berg, E.
    Folias, A.
    Bassoni, D.
    O'Mahony, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [49] T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis
    Semic-Jusufagic, Aida
    Ogese, Monday O.
    Edwards, Christopher
    Wilkinson, Mark
    Nissenbaum, Claire
    Lee, Tim
    Pirmohamed, Munir
    Naisbitt, Dean J.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (06)
  • [50] Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
    Rowe, Steven M.
    McColley, Susanna A.
    Rietschel, Ernst
    Li, Xiaolei
    Bell, Scott C.
    Konstan, Michael W.
    Marigowda, Gautham
    Waltz, David
    Boyle, Michael P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (02) : 213 - 219
12345